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Pancreatic cancer is a leading cause of cancer-related death due to its invasive nature.
Despite the improvement of diagnostic strategy, early diagnosis of pancreatic cancer
is still challenging. Surgical resection is the only curative therapy, while vast majority
of patients are not eligible for this therapeutic option. Complex biological processes
are involved in the establishment of invasion and metastasis of pancreatic cancer and
epithelial-mesenchymal transition (EMT) has been reported to play crucial role. EMT is
part of the normal developmental processes which mobilizes epithelial cells and yields
mesenchymal phenotype. Deregulation of EMT inducing molecules in pancreatic cancer
is reported, such as multiple cytokines, growth factors and downstream transcriptional
factors. In addition to these molecules, non-coding RNA including miRNA also contributes
to EMT. EMT of cancer cell also correlates with cancer stem cell (CSC) properties such as
chemoresistance or tumorigenicity, therefore these upstream regulators of EMT could be
attractive therapeutic targets and several candidates are examined for clinical application.
This review summarizes recent advances in this field, focusing the regulatory molecules
of EMT and their downstream targets. Further understanding and research advances
will clarify the cryptic mechanism of cancer metastasis and delineate novel therapeutic
targets.
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INTRODUCTION
Epithelial-mesenchymal transition (EMT) is a normal cellular
function which is indispensable during developmental processes
such as gastrulation or neural crest cell migration (Pla et al.,
2001; Nakaya and Sheng, 2008). However, pancreatic cancer cells
misuse this machinery for their invasion toward surrounding tis-
sue and dissemination into distant organs (Rhim et al., 2012).
Since invasion and metastasis are the key step for untreatable dis-
ease, numerous approaches have been made to prevent EMT of
pancreatic cancer cells. Unfortunately, these efforts have not yet
conquered the EMT of pancreatic cancer cells due to the complex,
cryptic mechanisms involved in this biological process.
Several cytokines and growth factors are reported to induce
EMT in pancreatic cancer cells. These factors are derived from
cancer cell itself (autocrine) or stromal cell (paracrine). For exam-
ple, transforming growth factor β (TGFβ) or its family member
bone morphogenetic protein (BMP) is reported to cause cellu-
lar morphological changes and altered expression of epithelial
markers (Fensterer et al., 2004; Hamada et al., 2007). In addition,
treatment of pancreatic cancer cells with vascular endothelial
growth factor (VEGF) also promotes EMT in pancreatic cancer
cells (Yang et al., 2006). These cytokines and growth factors uti-
lize wide variety of receptors and downstream signalingmolecules
which synergistically or redundantly contribute to the tumor
progression.
As a result of the cumulative gene mutations which
amplify oncogenic signal, aberrant activation of several signaling
pathways are observed in pancreatic cancer cells. Up to 95% of
pancreatic cancer harbors constitutively active mutation of K-ras
oncogene (Furukawa et al., 2006), which leads to the activation of
downstream signals for unlimited cellular proliferation. On the
other hand, specific gene deletion results in the defect of tumor
suppressive signal such as Smad4 deletion, which is observed in
50% of pancreatic cancer (Maitra and Hruban, 2008). Alteration
of these signaling pathways also contributes to the EMT induction
in pancreatic cancer cells.
Tumor microenvironment also influences the biological
behavior of pancreatic cancer. The characteristic feature of pan-
creatic cancer tissue is dense stroma surrounding tumor cells
which is called desmoplastic reaction (Mahadevan and Von
Hoff, 2007). The existence of desmoplastic reaction is reported
to contribute to pancreatic cancer progression. Recent research
identified a significant role of the tumor stromal cells in pan-
creatic cancer such as protection from chemotherapeutic agents
(Muerkoster et al., 2004) or metastasis-promoting role (Xu et al.,
2010). Based on these findings, tumor stromal cells are attracting
interest as a novel therapeutic target of pancreatic cancer.
Recent advances in the cancer research field identified an addi-
tional regulatory molecule of cellular functions. MicroRNA is a
member of non-coding RNA consists of 20–23 nucleotide which
targets 3′UTR sequence of mRNA for translational repression
and destabilization (Farazi et al., 2011). Several reports indicate
that microRNA could orchestrate biological processes by target-
ing hundreds of target mRNAs, including cancer cell invasion and
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metastasis (Sureban et al., 2011). There are several microRNAs
which contribute to pancreatic cancer cell migration and inva-
sion whose expression levels correlate with patients’ prognosis
(Ali et al., 2010a,b; Giovannetti et al., 2010).
These lines of evidences partially uncovered the complex
machinery which keep invasive growth of pancreatic cancer cells.
Dissecting the detailed mechanism of EMT in cancer cells will
elucidate novel therapeutic targets against invasion and metas-
tasis. Following sections describe current knowledge and future
perspectives in this field.
EMT-INDUCING CYTOKINES AND GROWTH FACTORS
TGFβ is a characteristic cytokine which possesses distinct effects
on cellular morphology and proliferation. TGFβ suppresses cel-
lular proliferation accompanied by the induction of cell cycle
regulator p21/waf1, whose induction requires intact Smad4 (Grau
et al., 1997). On the other hand, TGFβ causes down-regulation
of epithelial marker E-cadherin (Bardeesy et al., 2006) whose
expression attenuates invasive growth of pancreatic cancer cells
(Furuyama et al., 2000). Since TGFβ is enriched in plasma or
other extracellular sources (Labelle et al., 2011), this cytokine
is considered to be an important inducer of EMT during can-
cer progression. Similarly, a TGFβ family member BMP4 which
phosphorylates different Smad (Smad1, 5 and 8) from TGFβ
(Smad2 and 3) also induces EMT in pancreatic cancer cells via the
induction of MSX2 (Hamada et al., 2007; Gordon et al., 2009).
Interestingly, BMP4 also harbors growth inhibitory properties
accompanied by the induction of cell cycle regulator p21/waf1
(Kleeff et al., 1999; Hamada et al., 2009), suggesting redundant
roles of these family members which affect pancreatic cancer
progression.
Another growth factor is involved in the EMT induction of
pancreatic cancer. VEGF is a potent angiogenic factor which
stimulates endothelial cell proliferation and migration (Eilken
and Adams, 2010). A characteristic tissue structure of pancreatic
cancer, the desmoplastic reaction, hampers efficient blood per-
fusion which gives rise to increased hypoxia within the tumor.
Hypoxic condition stabilizes hypoxia-inducible factor 1α (HIF1α)
which promotes the transcription of VEGF mRNA (Dery et al.,
2005). VEGF also affects cellular morphology of pancreatic can-
cer cells featured by the loss of polarity, loose cell to cell contact
or decreased expression of the epithelial markers E-cadherin and
plakoglobin which is in accordance with EMT induction (Yang
et al., 2006).
Combination of multiple cytokines and growth factors depicts
synergistic effects in EMT induction. Fibroblast growth fac-
tor 2 (FGF-2) contributes to the EMT induction in trans-
formed epithelial cells as a downstream effector of HOXB7, a
homeodomain protein which is overexpressed in breast cancer
(Wu et al., 2006). Combined treatment of epithelial cells using
recombinant FGF-2 and TGFβ further enhances the migratory
phenotype (Shirakihara et al., 2011). This effect is mediated by
the altered expression of FGF receptor subtype by TGFβ which
sensitizes cells to FGF stimuli. Contribution of multiple cytokines
and growth factors during EMT could overwhelm the effect of
single-target therapy and enable redundant promotion of invasive
growth.
EMT AND INTRACELLULAR SIGNALING
As mentioned in the previous section, pancreatic cancer cells
are under the influence of various cytokines and growth fac-
tors. These extracellular stimuli activate intracellular signaling
molecules which contribute to the invasive phenotype of cancer
cells. Among these signaling molecules, the role of extracellular
signal-regulated kinase (ERK) pathway is well characterized dur-
ing EMT. Treatment of pancreatic cancer cell line Panc-1 by TGFβ
leads to the increased phosphorylation of ERKwhich is indispens-
able for the EMT induction by TGFβ (Ellenrieder et al., 2001).
Since ERK is activated by its upstream regulator Ras/Raf/MEK
pathway (Lopez-Chavez et al., 2009), activating mutation of Kras
could elevate the baseline activity of ERK pathway for further
amplification of TGFβ signal.
Besides the Ras/Raf/MEK/ERK pathway, inflammatory
signal-related pathway also plays important role for pancreatic
carcinogenesis. Previous report suggested that addition of
chronic inflammation by caerulein in genetically engineered
mice model expressing pancreas-specific Kras G12D significantly
enhanced the pancreatic cancer incidence (Guerra et al., 2007).
Among those inflammatory signal-related molecules, nuclear
factor kappa B (NFκB) plays aggravating role by inducing
pro-inflammatory cytokines which sustains chronic inflam-
mation within tumor (Ling et al., 2012). NFκB also promotes
EMT in pancreatic cancer cells by inducing mesenchymal
marker Vimentin and EMT-related transcriptional factor ZEB1
(Maier et al., 2010).
Aberrant activation of other signaling pathway is reported in
pancreatic cancer. Notch is a cell surface receptor which regu-
lates cell fate determination and differentiation during embry-
onic stage whose activation is also seen in pancreatic cancer
(Kimura et al., 2007). Acquisition of gemcitabine-resistant phe-
notype of pancreatic cancer cells is accompanied by the elevated
notch activity, whose silencing by siRNA attenuates the EMT
phenotype such as vimentin, ZEB1, Slug, and Snail expression
(Wang et al., 2009). Another signaling pathway, sonic hedgehog
pathway is also involved in pancreatic carcinogenesis whose orig-
inal role is an endodermal-mesodermal cross-talk during gut
development (van den Brink, 2007). Inhibition of hedgehog
pathway by several agents such as epigallocatechin-3-gallate or
IPI-269609 abrogated EMT phenotype of pancreatic cancer cells
(Feldmann et al., 2008; Tang et al., 2012). Targeting these signal-
ing pathways could be an effective therapy for EMT inhibition,
but complex cross-talk between multiple pathways could lead to
the resistance against single-agent therapy.
EMT AND TUMORMICROENVIRONMENT
The tumor microenvironment itself could exert EMT-promoting
effects. Hypoxia is a characteristic feature in pancreatic cancer tis-
sue, and besides the VEGF production, hypoxia alters intracellular
signals by up-regulating HIF1α. Twist is a transcriptional factor
involved in the EMT of pancreatic cancer cells (Satoh et al., 2008)
andHIF1α induces its expression (Sun et al., 2009). This is a direct
effect of hypoxia on cancer cells similar to the adaptation to the
hypoxic conditions (Pasteur effect).
When considering the cellular component within pancreatic
cancer stroma, the pancreatic stellate cells (PSC) should be
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emphasized as a central regulator of fibrosis. (Masamune and
Shimosegawa, 2009; Masamune et al., 2009; Erkan et al., 2012)
PSCs contribute to the formation of desmoplastic reaction by
producing extracellular matrix proteins such as fibronectin or col-
lagen (Bachem et al., 2005). These matrix proteins yield growth
stimulatory effects and EMT promotion (Kanno et al., 2008) on
pancreatic cancer cells which could be recognized as precondi-
tioning of cancer cells for metastasis.
Another report suggested that PSCs also contribute to estab-
lish metastatic site in vivo in collaboration with cancer cells
(Xu et al., 2010). The detailed mechanism for this phenomenon
remains elusive, but recent researches clarified the part of the
picture. Indirect co-culture of PSCs promotes EMT pheno-
type in pancreatic cancer cells independently of TGFβ (Kikuta
et al., 2010). This treatment also enhanced the cancer stem
cell (CSC) related genes’ expression and spheroid formation,
a hallmark of CSC function (Hamada et al., 2012a), suggest-
ing novel regulatory mechanism of PSCs in cancer metasta-
sis. Since PSC itself is a non-transformed cell, inhibition of
PSC function might be accomplished without acquiring ther-
apy resistance. Targeting cancer supporting cells could be a
promising therapeutic option. For the inhibition of PSC func-
tion, several signaling pathways are identified such as peroxi-
some proliferator-activated receptor-gamma, mitogen-activated
protein kinases, and reactive oxygen species which could be
modulated pharmaceutically (Masamune and Shimosegawa,
2009).
EMT-INDUCING microRNA
Recent advances in cancer research field identified novel
regulatory molecule in EMT. MicroRNA is a member of
non-coding RNA which targets hundreds of target mRNA,
thereby orchestrating cellular functions including EMT. Until
now, several microRNAs are reported to be involved in the reg-
ulation of pancreatic cancer cell motility and invasion. MiR-21
is highly expressed in pancreatic cancer compared with normal
tissue, and introduction of miR-21 precursor results in increased
cellular proliferation and invasion accompanied by the induction
of matrix metalloproteinase-2 and -9 (Moriyama et al., 2009).
Furthermore, miR-21 also contributes to the resistance against
gemcitabine and correlates with patient’s survival (Giovannetti
et al., 2010). Expression levels of microRNAs are measurable in
plasma samples, and their clinical application is expected. Serum
miR-21 expression level is elevated in patient with pancreatic can-
cer and correlated with poor survival, which indicates miR-21
could be an efficient biomarker of pancreatic cancer (Ali et al.,
2010a,b).
In contrast to the miR-21, EMT-inhibiting microRNA is
also identified by comprehensive analysis. By comparing the
microRNA expression profiles in invasive ductal adenocarcinoma
FIGURE 1 | A schematic view of EMT regulators in pancreatic
cancer development. Secreted cytokines such as TGFβ or BMP
activates intracellular signal which leads to the EMT induction. Activating
mutation such as Kras G12D constitutively stimulates intracellular signal
and amplifies extracellular signal. Endogenous alteration of microRNA
expression modifies cancer cell function. Stromal cells including
PSCs establish protective microenvironment for cancer cells such as
desmoplasia.
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with intraductal papillary mucinous neoplasm, the miR-126 was
identified as a significantly down-regulated microRNA in invasive
ductal adenocarcinoma (Hamada et al., 2012b). Database analysis
identified that miR-126 potentially targets disintegrin and met-
alloproteinase domain-containing protein 9 (ADAM9), which is
highly expressed in pancreatic cancer (Grutzmann et al., 2004).
Expression of miR-126 and ADAM9 were mutually exclusive,
and re-expression of miR-126 attenuated pancreatic cancer cell
migration and invasion (Hamada et al., 2012b). These findings
suggest the multimodal regulation of EMT during pancreatic
cancer progression.
CONCLUSION
This review summarized the current knowledge about the reg-
ulatory mechanisms of EMT. The schematic view of these reg-
ulators of EMT is shown in Figure 1. Inhibition of specific
cytokines, growth factors or signaling pathways met their limi-
tations for clinical applications due to the redundant regulation
of EMT in pancreatic cancer. Targeting normal cells such as
endothelial cells, immune cells, or stromal cells which sus-
tain cancer microenvironment would be novel therapeutic tar-
gets against cancer invasion and metastasis. In addition to
this concept, a comprehensive regulator of cellular function,
microRNA could be a powerful tool in regulating metastasis-
promoting microenvironment. Further understanding about the
EMT regulation will provide efficient therapy against pancreatic
cancer.
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